GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CuraScientific Corp (OTCPK:CSTF) » Definitions » Debt-to-Equity

CuraScientific (CuraScientific) Debt-to-Equity : -0.03 (As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is CuraScientific Debt-to-Equity?

CuraScientific's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.64 Mil. CuraScientific's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.09 Mil. CuraScientific's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-24.78 Mil. CuraScientific's debt to equity for the quarter that ended in Sep. 2023 was -0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CuraScientific's Debt-to-Equity or its related term are showing as below:

CSTF' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.04   Med: -0.02   Max: 0
Current: -0.03

CSTF's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.29 vs CSTF: -0.03

CuraScientific Debt-to-Equity Historical Data

The historical data trend for CuraScientific's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CuraScientific Debt-to-Equity Chart

CuraScientific Annual Data
Trend Dec20 Dec21 Dec22
Debt-to-Equity
- -0.02 -0.04

CuraScientific Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.04 - -0.02 -0.03

Competitive Comparison of CuraScientific's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, CuraScientific's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CuraScientific's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CuraScientific's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CuraScientific's Debt-to-Equity falls into.



CuraScientific Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CuraScientific's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

CuraScientific's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CuraScientific  (OTCPK:CSTF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


CuraScientific Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CuraScientific's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


CuraScientific (CuraScientific) Business Description

Traded in Other Exchanges
N/A
Address
51544 Cesar Chavez Street, Suite No. 1J, Coachella, CA, USA, 92236
CuraScientific Corp manufactures commercial chemicals with a variety of commercial sterilization applications for agriculture, warehousing, hospitality, and medical facilities. The company's product, DiOx+, is a disinfectant sterilizer that kills harmful pathogens without exposing people or the environment to dangerous toxins.
Executives
Paul Quentin Goyette director 2205 LOCH WAY, EL DORADO HILLS CA 95762
William Joseph Reed director, officer: Chief Executive Officer 333 N UNIVERSITY AVE., #33, REDLANDS CA 92374
Johann Loewen director C/O METHES ENERGIES INTERNATIONAL LTD, 3651 LINDELL ROAD, SUITE D-272, LAS VEGAS NV 89103
Edouard Maurice Beaudette director 13480 N BLOOMFIELD ROAD, NEVADA CITY CA 95959
Justin Michael Gonzalez director, officer: Chief Executive Officer 15723 LAKE VERA PURDON RD., NEVADA CITY CA 95959
Eric Jason Watson director, officer: Chief Operating Officer 19553 BOWERS DRIVE, TOPANGA CA 90290

CuraScientific (CuraScientific) Headlines

From GuruFocus

Introducing Leaf of Faith

By Marketwired Marketwired 03-26-2019